Abstract:The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodomain extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two most relevant non-BET bromodomain oncology targets are cyclic AMP response element-binding protein (CBP) and E1A binding protein P300 (EP300). To explore the growing CBP/EP300 interest, we developed a highly efficient two-step synthetic route for dimethylisoxazole-attached imidazo[1,2-a]pyridine scaffold-containing inhibitors. Our efficient two-step reactions enabled high-throughput synthesis of compounds designed by molecular modeling, which together with structure–activity relationship (SAR) studies facilitated an overarching understanding of selective targeting of CBP/EP300 over non-BET bromodomains. This led to the identification of a new potent and selective CBP/EP300 bromodomain inhibitor, UMB298 (compound 23, CBP IC50 72 nM and bromodomain 4, BRD4 IC50 5193 nM). The SAR we established is in good agreement with literature-reported CBP inhibitors, such as CBP30, and demonstrates the advantage of utilizing our two-step approach for inhibitor development of other bromodomains.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02232?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02232</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_001.csv">CSV</a>)BromoSCAN, differential scanning fluorometry (DSF), and cellular activity data of compounds 7, 16, and 23; crystallographic data collection and refinement statistics of compound 23; 1H NMR and 13C NMR of representative compounds; and HPLC traces of compounds 7, 16, and 23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_002.pdf">PDF</a>)Homology (docking) models of BRD4_5BT4_Cpd7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_003.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_004.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_005.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-3 (UMB274) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_006.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-4 (UMB278) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_007.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_008.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_009.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_010.pdb">PDB</a>)Cocrystallographic data of compound 23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_011.pdb">PDB</a>)This article has not yet been cited by other publications.

Lead Discovery, Chemistry Optimization, and Biological Evaluation Studies of Novel Biamide Derivatives As CB2 Receptor Inverse Agonists and Osteoclast Inhibitors.

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB 2 Receptor Inverse Agonists.

Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects

Structure activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the 'message-address concept' to comprehend their functional conversion.

Design, Synthesis and Anti-Inflammatory Evaluation of 3-Amide Benzoic Acid Derivatives As Novel P2Y14 Receptor Antagonists.

Synthesis and biological evaluation of heterocyclic ring-fused betulinic acid derivatives as novel inhibitors of osteoclast differentiation and bone resorption.

Discovery of N-Substituted Acetamide Derivatives as Promising P2Y 14 R Antagonists Using Molecular Hybridization Based on Crystallographic Overlay

Structure-Activity Relationships and Molecular Pharmacology of Positive Allosteric Modulators of the Mu-Opioid Receptor

Investigations into the anti-inflammatory and anti-diabetic activity of newly synthesized derivatives of 4AP2BOB utilizing DFT, molecular docking and spectroscopic characterization

Synthesis and Biological Evaluation of Novel Biased Mu-Opioid Receptor Agonists

Synthesis and SAR Study of Novel Diimide Skeleton Compounds with the Anti-Inflammatory Activities in Vitro and in Vivo.

3-Benzyl-1,3-oxazolidin-2-ones As Mglur2 Positive Allosteric Modulators: Hit-to Lead and Lead Optimization

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Discovery of 4-(1,2,4-oxadiazol-5-yl)azepan-2-one Derivatives As a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain

Synthesis and Structure–Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents

Development of Dimethylisoxazole-Attached Imidazo[1,2- a ]pyridines as Potent and Selective CBP/P300 Inhibitors

Synthesis and discovery of novel pyrazole carboxamide derivatives as potential osteogenesis inducers.